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Integrated testing strategy (ITS)Sensitization, the prerequisite event in the development of allergic contact dermatitis, is a key parameter
in both hazard and risk assessments. The pathways involved have recently been formally described in the
OECD adverse outcome pathway (AOP) for skin sensitization. One single non-animal test method will not
be sufﬁcient to fully address this AOP and in many cases the use of a battery of tests will be necessary. A
number of methods are now fully developed and validated. In order to facilitate acceptance of these
methods by both the regulatory and scientiﬁc communities, results of the single test methods (DPRA, Ker-
atinoSens™, LuSens, h-CLAT, (m)MUSST) as well for a the simple ‘2 out of 3’ ITS for 213 substances have
been compiled and qualitatively compared to both animal and human data. The dataset was also used to
deﬁne different mechanistic domains by probable protein-binding mechanisms. In general, the non-ani-
mal test methods exhibited good predictivities when compared to local lymph node assay (LLNA) data
and even better predictivities when compared to human data. The ‘2 out of 3’ prediction model achieved
accuracies of 90% or 79% when compared to human or LLNA data, respectively and thereby even slightly
exceeded that of the LLNA.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Allergic contact dermatitis (ACD1) is the clinically relevant out-
come of skin sensitization and it is estimated that 15–20% of the gen-
eral population will be sensitized at some point in the course of theirlives (Thyssen et al., 2007; Bruckner et al., 2000). ACD can be associ-
ated with morbidity, affect the quality of life, and sensitization –
the prerequisite for the development of ACD – is usually a lifelong
effect. Sensitization is considered to be one of the key human health
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result of a complex multifactorial sequence of events. The chemical
and biological pathways involved are relatively well characterized
and can be simpliﬁed and structured into an adverse outcome path-
way (AOP). The key events involved have now been formally
described by the OECD in a document titled ‘‘The Adverse Outcome
Pathway for Skin Sensitization Initiated by Covalent Binding to
Proteins’’ with the goal of facilitating the development of methods
and approaches addressing the relevant events (ENV/JM/
MONO(2012)10/PART 1 and 2).
Contact allergies develop in two stages: (1) the sensitization
phase in which antigen/allergen speciﬁc T-cells are generated,
and (2) the elicitation phase in which renewed contact with the
allergen leads to the allergic response (Goebel et al., 2012). Follow-
ing entry into the skin, the AOP described by the OECD identiﬁes
eleven events involved whereby four are considered to be key
events. The initiating event of the sensitization process is the cova-
lent binding of a hapten, a low molecular weight (LMW) and typi-
cally electrophilic substance, to the skin proteins. This is the
essential event to transform an otherwise non-immunogenic mol-
ecule into a potential allergen. The protein reactivity of the sub-
stance may be inherent or can develop following metabolic or
abiotic transformations of the pro- or pre-haptens, respectively
(Gerberick et al., 2008; Jäckh et al., 2012). Key event 2 is the acti-
vation of keratinocytes. Keratinocytes are the main cell population
of the epidermis and are the ﬁrst cells to come into contact with
the potential allergen. Keratinocytes may respond to the contact
with the hapten and/or the complete allergen. Among these
responses, the oxidative and electrophilic stress-driven expression
of genes under the control of the antioxidant response element
(ARE) as part of the Keap1/Nrf2 pathway is well described
(Natsch and Emter, 2008). The third key event is the activation of
dendritic cells. Dendritic cells take up and process antigens and
present fragments in form of major histocompatibility complexes
(MHC) on their surfaces. Dendritic cells mature during this process
and migrate to the lymph nodes. Mature dendritic cells are charac-
terized by the up-regulation of cell surface markers such as CD54
and CD86 in order to activate naïve T-cells. The ﬁnal event of the
sensitization phase is the proliferation of the antigen-speciﬁc T-
cells and the generation of antigen-speciﬁc memory T-cells
(Goebel et al., 2012).
In the regulatory context, the skin sensitization potential of a
chemical has traditionally been evaluated using animal tests, in
particular the guinea-pig based tests (GPTs) described in OECD
406 or the mouse-based local lymph node assay (LLNA) described
in OECD 429 (or OECD 442 A + B). The 7th amendment of the Cos-
metic Directive (Council Directive 76/768/EEC of 1976-07-27; now
Cosmetics Regulation: REGULATION (EC) No. 1223/2009), imple-
mented a phasing out of animal testing for the purposes of this leg-
islation. This in turn has made the development and use of non-
animal tests for new cosmetic substances indispensable. Other leg-
islations have followed or are in the process of following suit, and
explicitly permit animal testing only as a last resort, e.g. the cur-
rent European substances legislation Nr. 1907/2006 [Registration,
Evaluation, Authorization and Restriction of Chemicals (REACh)].
Of the human health endpoints to be assessed under REACh, skin
sensitization must be evaluated for all substances to be registered.
In REACh phase 1 more than 3700 substances were assessed for
skin sensitization (Angers-Loustau et al., 2011) and several thou-
sand more are expected for REACh phase 3 until 2018.
The current consensus among the scientiﬁc community is that
one single non-animal test might not be sufﬁcient as a stand-alone
method to cover the endpoint skin sensitization and that the use of
an integrated testing strategy (ITS; in this context ITS includes
sequential testing strategies (STS), etc.) will be necessary
(Mehling et al. 2012, Rovida et al. 2014; Basketter et al., 2013).Currently, two tests, namely the direct peptide reactivity assay
(DPRA) (Gerberick et al., 2004) and the ARE–Nrf2 luciferase test
method KeratinoSens™ (Emter et al., 2010) have passed the valida-
tion process at ECVAM and a statement of the ECVAM Scientiﬁc
Advisory Committee (ESAC) has been published regarding their
use within integrated testing approaches and assessments (IATA)
(EURL ECVAM, 2013; EURL ECVAM, 2014); the OECD draft guide-
lines have been drafted and are in the ﬁnal stages of the commen-
tation process. The ECVAM recommendation and ESAC statement
as well as an OECD draft guideline are available for a third test,
namely the human cell-line activation test (h-CLAT) (Ashikaga
et al., 2006). In addition, validation studies are ongoing for the
LuSens assay (Bauch et al., 2012; Ramirez et al., 2014), an ARE–
Nrf2 luciferase test method similar to the KeratinoSens™. Data
on over a hundred substances is available for the myeloid U937-
based skin sensitization tests MUSST (myeloid U937 skin sensitiza-
tion test) (Ade et al., 2006) and the modiﬁed MUSST (mMUSST)
(Bauch et al., 2011, 2012). The MUSST is also in the validation at
ECVAM (ECVAM Test Method Submissions 2008–2014).
Integrated approaches to testing and assessment (IATA) and in
particular the integrated testing strategies (ITS) used within the
IATA should consist of methods with a mechanistic relevance for
the endpoint being assessed. Placed in the context of the AOP,
the DPRA evaluates key event 1 – the protein/peptide reactivity
of a substance, the KeratinoSens™ and LuSens assays represent
key event 2 and give a measure keratinocyte activation, and the
h-CLAT, MUSST and mMUSST describe key event 3 – dendritic cell
activation. Thus, when used together, they cover the ﬁrst three of
the four key events of the sensitization process, thus being of
mechanistic relevance and supporting the scientiﬁc rationale for
using a combination of these methods in an AOP-based ITS. Indeed,
these tests are already being successfully used in combination in a
number of ITS which include, but are not limited to, the ‘2 out of 3’
approach (also sometimes termed majority vote or ‘2 out of 3’
weight of evidence (WoE) approach (Bauch et al., 2012; Natsch
et al., 2013; van der Veen et al., 2014)), an ITS based on Bayesian
Networks (Jaworska et al., 2013) and an ITS which includes an
assessment of potency (Nukada et al., 2013; Tsujita-Inoue et al.,
2014). Currently, the OECD in conjunction with EURL ECVAM is
developing a document describing the key elements of an (AOP-
based) IATA and designing templates for reporting an ITS. Accord-
ing to the roadmap proposed by EURL ECVAM submission of the
document to the OECD should take place in 2016 (Kinsner-
Ovaskainen et al., 2012). Whether this document will be accepted
in time for the testing phase preceding the REACh phase 3 (sub-
stances with an annual production tonnage of 1–100 tons) dead-
line is currently unknown.
As risk assessments are based on hazard assessments, the ﬁrst
goal is to adequately address the skin sensitization hazard poten-
tial of a substance. A study conducted by ECVAM on all registered
substances in the new substances data base, revealed that 2745 of
the evaluated 3792 substances were not classiﬁed (NC; approx.
72%) for sensitization and that 1047 (about 28%) were classiﬁed
as sensitizers (Angers-Loustau et al., 2011). This indicates that if
a sensitization potential (hazard) can be excluded, further informa-
tion on potency for risk assessments or classiﬁcation according to
the Globally Harmonized System (GHS) would only be needed for
approximately 30% of the substances. Regulatory acceptance, e.g.
for GHS classiﬁcation and/or REACh registration, and the use of
non-animal tests for safety assessments is critically dependent
on the correct predictivities of a method or an ITS. This in turn is
supported by the availability of data allowing the evaluation of
the types of substances tested and the limitations/strengths of
the methods or ITS. Only such data driven analysis will help to
build conﬁdence to use the new approaches. This was also a key
message from a workshop at which regulators and industry dis-
D. Urbisch et al. / Regulatory Toxicology and Pharmacology 71 (2015) 337–351 339cussed how to best facilitate acceptance of non-animal methods
and ITS (Basketter et al., 2013).
This manuscript compiles and evaluates the available data –
both previously published and unpublished – obtained with the
above mentioned in vitro methods to help facilitate the acceptance
of non-animal testing approaches for the toxicological endpoint
‘skin sensitization’. The predictivities of the individual methods
are evaluated as is their use in one ITS for skin sensitization hazard
assessment, namely the ‘2 out of 3’ approach. The evaluation was
limited to this example of an ITS as the design of an ITS needs to
be adapted depending on the assessments being made, e.g. an ITS
for risk assessments will usually differ from an ITS for hazard
assessments. Additionally, ﬂexibility is needed, e.g. if the ITS is part
of a read across approach, if some methods may not be available at
contract research institutes, or if an ITS has proprietary elements.
Therefore, only the weight of evidence based ‘2 out of 3’ approach
for hazard assessments which is based on the ﬁrst three key events
of the adverse outcome pathway was assessed. In this study, the
applicability of the test methods and ITS for different substance
properties and mechanisms of reactivity was also assessed. The
compilation of non-animal test method results for over 200 sub-
stances now provides a very comprehensive data base which
exceeds that used for the formal validation of the ‘‘benchmark’’
animal method – the LLNA.2. Materials and methods
2.1. Data set
The data set consists of both previously published (Natsch et al.,
2013; Nukada et al., 2012; Bauch et al., 2012) and additional
unpublished data for 213 test substances. All substances, physico-
chemical properties, types of use, test data, proposed reaction
mechanisms as well as related references and data bases are listed
in Supplementary Table (supporting information). Fig. 1 shows the
use categories of these substances.
For 208 substances, high quality LLNA data were described in
the literature or data bases; for 5 substances hitherto unpublished
LLNA data were used. Of the 213 substances evaluated in this
study, 151 (71%) are considered to be sensitizers and 62 (29%) to53 
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Fig. 1. Schematic representation of the uses of the investigated substances. The
numbers of substances for each use are indicated in parentheses as well as in the
pie chart itself. Blue – fragrances (n = 53), dark green – preservatives/disinfectants
(n = 26), light green – dyes (n = 12), dark red – monomers (n = 15), mint green –
pesticides (n = 9), red – solvents (n = 8), white – cosmetics (n = 14), yellow –
pharmaceuticals (n = 9), light blue – surfactants (n = 5), pink – plasticizers (n = 3),
orange – food/feed (n = 4), gray – other uses (n = 55).be non-sensitizers according to available LLNA data. In addition,
human data were available for 114 of these substances. For all sub-
stances within this data compilation, results were available for at
least two of the investigated non-animal test methods. The set of
non-animal test data comprises data originating from the DPRA
(results for 199 substances), KeratinoSens™ (results for 195 sub-
stances), LuSens (results for 77 substances), h-CLAT (results for
166 substances), MUSST (results for 145 substances) and mMUSST
data (results for 65 substances). In order to create mechanistic
domains from a chemical perspective, the putative reaction mech-
anisms for peptide reactivity of the 213 substances was evaluated
using the freely available OECD QSAR Toolbox v3.2 and searching
the scientiﬁc literature.
2.2. Non-animal test methods
2.2.1. Direct peptide reactivity assay (DPRA)
Peptide reactivity data were generated using a method to mea-
sure reactivity of a test chemical with model hepta-peptides con-
taining lysine (Ac-RFAAKAA-COOH) or cysteine (Ac-
RFAACAACOOH) (Gerberick et al., 2004). Peptide reactivity was
reported as percent depletion based on the decrease in non-reacted
peptide concentration in the sample relative to the average concen-
tration measured in the control.
Peptides were prepared and puriﬁed by the SynPep Corporation
(Dublin, CA, USA) to >90% purity as measured by HPLC, and molec-
ular weight conﬁrmation was determined by ﬂow injection posi-
tive-ion electrospray mass spectrometry. Brieﬂy, 400 lL of a
1.25 mM peptide stock solution prepared in buffer and a 100 mM
test chemical stock solution prepared in either acetonitrile or
DMSO/acetonitrile were added to 100 mM ammonium acetate buf-
fer (pH 10.2) for the lysine peptide or 100 mM sodium phosphate
buffer (pH 7.5) for the cysteine peptide. The ﬁnal reaction, contain-
ing 0.5 mM of the peptide and 5 or 25 mM of the test chemical,
representing 1:10 and 1:50 M ratios, was mixed and incubated in
the dark for 24 h at 25 C. Control samples and standards used
for deﬁning the calibration curve for each analysis were prepared
without test chemical for each peptide and ranged from 0.0156
to 1.0 mM. All samples were prepared in triplicate. Following incu-
bation, the peptide was quantiﬁed by reverse-phase HPLC (Waters
2695 Alliance) on a Zorbax SB-C18 column (3.5 lm, 100  2.1 mm)
with UV detection at 220 nm (Waters 996 PDA detector) using an
external standard linear calibration curve. The UV spectrum was
collected from 210 to 400 nm to permit veriﬁcation of the peptide
peak identity. Results for 199 substances were generated by P&G
(referred to in Supplementary Table as DPRA I) or BASF (DPRA II)
and thus available for this study. Five substances were not consid-
ered for further analyses due to discordant results in the two inde-
pendent labs.
2.2.2. KeratinoSens™ assay
The standard operating procedure described (Natsch et al.,
2011) and published online (ECVAM, 2014) was used to test addi-
tional substances in the KeratinoSens™ assay. Brieﬂy, cells were
grown for 24 h in 96-well plates. The medium was then replaced
with medium containing the test substance and a ﬁnal level of
1% of the solvent DMSO. Each test substance was subsequently
tested at 12 twofold dilutions (0.98–2000 lM). In each repetition,
three parallel replicate plates were run for luciferase determina-
tion and a fourth parallel plate was prepared for cytotoxicity deter-
mination. Cells were incubated for 48 h with the test substances,
and then luciferase activity and cytotoxicity (with the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid (MTT)
assay (Mosmann, 1983)) were determined. For each chemical the
EC1.5, EC2 and EC3 values (concentration in lM for 1.5, 2 and 3-
fold induction of the luciferase activity) were calculated along with
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viability. Substances were tested in at least two independent
experiments. A substance is considered to have a sensitizing poten-
tial if an induction equal to or exceeding 1.5-fold compared to the
vehicle control is observed at a concentration below 1000 lM and
at which cells remain >70% viable. If the results of the two exper-
iments were concordant, a prediction according to the prediction
model was derived. Substances with discordant results or results
close to the 1.5-fold threshold (borderline) were tested in addi-
tional independent experiments. The number of experiments and
the number of positive results for each chemical is given in the
database. Results for 195 substances were generated by Givaudan
(referred to in Supplementary Table as KeratinoSens assay I) or
BASF (KeratinoSens assay II) and thus available for this study. Eight
substances were not considered for further analyses due to discor-
dant results in the two independent labs.
2.2.3. LuSens assay
The LuSens assay is a keratinocyte-based assay which utilizes
the luciferase gene under the control of the antioxidant response
element (ARE) originating from the rat NQO1 gene as the reporter
construct. The LuSens assay used in this paper is similar to that
described in Bauch et al., 2012 with some modiﬁcations (Ramirez
et al., 2014). In brief, a cytotoxicity range ﬁnding experiment (con-
sisting of twelve concentrations) was performed, to calculate the
concentration in which cell viability corresponds to no less than
75% (CV75). Following the range ﬁnder experiment, a main exper-
iment was set up using six concentrations of test substance (in
triplicates), the highest tested concentration was 1.2 CV75 (or
2000 lM if no cytotoxicity was observed). After 48 h treatment,
luminescence and cytotoxicity were measured. A test substance
is considered to have skin sensitization potential when the lucifer-
ase induction is above or equal to 1.5-fold compared to the vehicle
control in two (or more than) consecutive non-cytotoxic tested
concentrations whereby at least three tested concentrations must
be non-cytotoxic (viability P70%). A test compound is considered
not to have sensitizing potential if the above effects are not
observed. The skin sensitization potential of a test substance is
determined by the result of the majority of the repetitions of an
experiment. If two of two or two of three repetitions are nega-
tive/positive, the substance is considered as negative/positive. In
order to come to a conclusion on the skin sensitization hazard of
a substance, one complete experiment needs to be conducted. A
complete experiment consists of two valid independent repetitions
(Ramirez et al., 2014). Results for 77 substances were obtained by
BASF and considered for this study.
2.2.4. Human cell line activation test (h-CLAT)
In the h-CLAT assay, THP-1 cells (American Type Culture Collec-
tion, Manassas, VA, USA) were used as surrogate for dermal den-
dritic cells. For dose ﬁnding, cytotoxicity tests were conducted
and the concentration resulting in 75% cell viability, termed
CV75, was calculated based on the analysis of viable cells. THP-1
cells were treated with eight different concentrations, decided
based on dose ﬁnding cytotoxicity test, for 24 h. After removing
the test substance, the expression of CD86 and CD54 on the cell
surface was measured by ﬂow cytometry. The relative ﬂuorescence
intensity (RFI) was used as an indicator of CD86 and CD54 expres-
sion. If the RFI of CD86 or CD54 was greater than 150% or 200% at
any dose in at least two out of three experiments, the substance
was judged as a sensitizer. Otherwise, it was considered a non-sen-
sitizer (Ashikaga et al., 2006). From the dose-dependency curves of
three experiments, the median concentration inducing 150% of
CD86 RFI and/or 200% of CD54 RFI (EC150 or EC200) was calculated
like EC3 value determination in the LLNA. The lower EC value was
deﬁned as minimal induction threshold (MIT) (Nukada et al.,2013). Results for 166 substances were available for this study
and for the determination of Cooper statistics; data generated by
the respective method developer was used.
2.2.5. Myeloid U937 skin sensitization test (MUSST) and modiﬁed
MUSST
The MUSST uses the U937 cell-line purchased from the Ameri-
can Type Culture Collection (Rockville, MD, USA). Four to six con-
centrations are chosen based on preliminary propidium iodide
cytotoxicity experiments and are applied in duplicate for 48 h.
The highest tested concentration in the main experiment is twice
the concentration causing a cytotoxicity of 25% (CV75) determined
in a pretest. A test substance is predicted to have a dendritic cell
activating potential indicative of being a sensitizer when CD86
induction (measured by ﬂow cytometry) exceeds the threshold of
1.5-fold with respect to vehicle treated cells at any tested concen-
tration showing sufﬁcient cell viability (P70%) in at least two inde-
pendent experiments (Natsch et al., 2013). Results for 145
substances were made available for this study by P&G (referred
to in Supplementary Table as U-937 Test).
A modiﬁed version of the MUSST (mMUSST) uses the U937 cell
line from German Resource Center for Biological Material DSMZ,
Braunschweig, Germany. In the mMUSST, a test substance is pre-
dicted to have a dendritic cell activating potential when CD86
induction exceeds a threshold of 1.2-fold (Bauch et al., 2012). Data
for 65 substances were generated in the mMUSST by BASF
(referred to in Supplementary Table as mMUSST).
For the analyses within this study, the results from the MUSST
and mMUSST were taken together to create a dataset of 161 sub-
stances. Data for 12 substances were not further considered for
analyses due to discordant results being obtained in both tests.
2.2.6. ‘2 out of 3’ prediction model
The least complicated way to assess the skin sensitization haz-
ard potential of a substance is to use the results of single assays
which reﬂect key steps of the AOP within a ‘2 out of 3’ prediction
model. For the assays addressing the three key events described
in the OECD AOP on skin sensitization mentioned above, a ‘2 out
of 3’ assessment was introduced for the ﬁrst time by Bauch et al.
(2012). In the current study, this prediction model was applied
using DPRA, KeratinoSens™ and h-CLAT data. Any two congruent
results of the three tests rule the overall assessment: If at least
two of the three assays were positive, the substance was rated to
be a skin sensitizer. If at least two of the three assays were nega-
tive, the substance was rated to be a non-sensitizer. The classiﬁca-
tion as a sensitizer or non-sensitizer is therefore based on a weight
of evidence pertaining to key events of the AOP. Cooper statistics
for this classiﬁcation were determined in comparison to LLNA or
human data. Results for 180 or 101 substances, respectively, were
obtained using this prediction model.
2.2.7. OECD QSAR Toolbox
The QSAR Toolbox developed by OECD in collaboration with the
European Chemical Agency (ECHA) (Raunio, 2011) is a standalone
software application for ﬁlling gaps of (eco)toxicity data that are
needed to assess the potential hazards of substances. In silico anal-
ysis was performed with the OECD QSAR Toolbox in the version
3.2., which is freely available on the OECD website (http://tool-
box.oasis-lmc.org/?section=download&version=latest). In order to
support the identiﬁcation of a chemical’s toxicity, the OECD QSAR
Toolbox contains numerous databases with results from experi-
mental studies for over 55.000 substances and proﬁlers for calcu-
lating speciﬁc properties (references are added at each proﬁler
within this tool). Two such proﬁlers are the protein-binding proﬁl-
ers based on OECD and OASIS algorithms (‘‘Protein binding by
OECD’’, ‘‘Protein binding by OASIS v1.2’’). In order to also identify
D. Urbisch et al. / Regulatory Toxicology and Pharmacology 71 (2015) 337–351 341substances, which require abiotic or metabolic activation, the
‘‘auto-oxidation proﬁler’’ and the ‘‘skin metabolism proﬁler’’ were
used Teubner et al., 2013.
2.2.8. Cooper statistics
The Cooper statistics of predictivity were calculated for the sin-
gle assays as well as for the ‘2 out of 3’ prediction model (Cooper
et al., 1979). All parameters are based on a 2  2 contingency table
counting the number of compounds that are ‘‘true positive’’ (TP),
‘‘false positive’’ (FP), ‘‘true negative’’ (TN) and ‘‘false negative’’ (FN):
Sensitivity ½% ¼ TP
TPþ FN  100
Specificity ½% ¼ TN
TNþ FP  100
Positive predictive value ½% ¼ TP
TPþ FP  100
Negative predictive value ½% ¼ TN
TNþ FN  100
Accuracy ½% ¼ TPþ TN
TPþ FPþ TNþ FN  1003. Results
3.1. Availability of in vivo data
Due to the fact that human data were available for only a lim-
ited number of substances, two different sets of substances were
deﬁned (Table 1). Murine LLNA data were available for all 213 sub-
stances (set A) whereas additional human data were available for a
subset of 114 substances (subset B). No reliable human data were
found in the literature or data bases for 99 substances (data were
not further analyzed for this group). In subset B, direct compari-
sons of non-animal test results to both human and LLNA data were
possible.
3.2. Predictivities compared to LLNA and human data
Detailed results (including concentration–response data, cyto-
toxicity information, peptide depletions) of the investigated assays
are listed in Supplementary Table (supporting information). When
calculating the Cooper statistics (Table 2), the assessments were
reduced to yes/no ratings according to the prediction models of
the individual assays. It should be noted that data for all 213 sub-
stances was not available for every assay. The number of tested
substances being considered for further analyses hence ranges
from n = 77 (LuSens) to n = 194 (DPRA). Accuracies of the single
assays compared to LLNA data range from 73% to 76% (Table 2,Table 1
Sensitizers and non-sensitizers among substances with LLNA data and with human
data on skin sensitization.
Chemical set and reference data Set A Subset B
LLNA data Human data LLNA data
Sensitizer 151 75 83
Non-sensitizer 62 36 31
Borderline 0 3 0
Total 213 114 114
(A) All substances within the data set (n = 213) with available LLNA data. (B) Sub-
stances within the data set (n = 114) with available human data.set A). The ‘2 out of 3’ approach (DPRA, KeratinoSens™ and h-CLAT
data) provides an accuracy of 79% when compared to LLNA data.
Using the data from subset B, a direct comparison between the
predictivities of the non-animal test methods and human or LLNA
data is possible (Table 3). Interestingly, when comparing the Coo-
per statistics of almost all single non-animal test methods with
human data, the percentages were higher than comparisons with
LLNA data (Table 3). The ‘2 out of 3’ approach (DPRA, Keratino-
Sens™ and h-CLAT data) provides somewhat higher accuracies
compared to the predictivities of the single assays, whereby the
accuracies compared to human or LLNA data were 90% or 82%,
respectively. These results indicate that the investigated non-ani-
mal methods generally predict human data more accurately than
LLNA data.
To determine the performance of the LLNA to predict skin sen-
sitization hazard of this data set, LLNA data were directly com-
pared to the available human data for the substances within
subset B. A total of 20 (18%) of the substances were incorrectly
identiﬁed as FN or FP by the LLNA. Seven substances were assessed
to be FN (benzaldehyde, benzyl alcohol, coumarin, streptomycin
sulfate, kanamycin, benzocaine and nickel chloride) and 13 to be
FP (pyridine, limonene, isopropyl myristate, citronellol, linalool,
a-iso-methylionone, benzyl benzoate, SDS, tocopherol, benzyl
salicylate, hexyl salicylate, xylene and phthalic anhydride). In total,
comparison to human data revealed a sensitivity of 91%, a speciﬁc-
ity of 64% and an overall accuracy of 82% of the LLNA (Table 3). For
comparison, the ‘2 out of 3’ prediction model revealed a sensitivity
of 90%, a speciﬁcity of 90% and an overall accuracy of 90% for the
same set of substances suggesting predictions to be more relevant
for humans.
3.3. Comparing results of single assays in different labs
3.3.1. Interlaboratory reproducibilities
For some of the 213 substances the DPRA, KeratinoSens™ and
(m)MUSST were conducted in two labs enabling tentative analyses
of interlaboratory reproducibilities. Within this study, 45 sub-
stances were tested in the DPRA in two labs (P&G and BASF).
Among these, 40 substances gave congruent (89%) and ﬁve sub-
stances gave incongruent results. 52 Substances were tested in
the KeratinoSens™ assay in two labs (Givaudan and BASF). Here,
44 substances gave congruent (85%) and eight substances gave
incongruent qualitative outcomes. Comparing MUSST and
mMUSST results obtained at P&G and BASF, the analyses of 45 sub-
stances resulted in 32 congruent (71%) and 13 incongruent qualita-
tive outcomes (this comparison needs to be viewed in the light of
slightly different protocols and use of the 1.5-fold and 1.2-fold
CD86 induction cut-off, respectively). Substances with incongruent
results were excluded from subsequent analyses.
3.3.2. Interchangeabilities
Since both the KeratinoSens™ and the LuSens address keratino-
cyte activation and the h-CLAT and (m)MUSST address dendritic
cell activation, interchangeabilities of the assays representing the
same AOP key event were analyzed based on predicitivities of
the assays and in the ‘2 out of 3’ approach.
A set of 69 substances was tested in the KeratinoSens™ (Givau-
dan) and the LuSens assay (BASF). The same overall outcome for 61
of the 69 substances resulted in an interchangeability of 88%. The
discordant substances among the two ARE activation assays are
listed in Table 11. The KeratinoSens™ offered an accuracy of 75%
or 83% and the LuSens an accuracy of 71% or 79%, when comparing
the results to LLNA or human data, respectively. The implementa-
tion of the KeratinoSens™ into a ‘2 out of 3’ approach with DPRA
and h-CLAT data for the set of 69 substances resulted in an accu-
racy of 85% or 91%, when comparing the predictions to LLNA or
Table 2
Cooper statistics for the single non-animal test methods and the ‘2 out of 3’ approach for the whole data set (set A).
Chemical set and reference data Set A
LLNA data
Cooper statistics Sensitivity [%] Speciﬁcity [%] Accuracy [%] n
‘2 out of 3’ approach 82 72 79 180
DPRA 76 72 75 194
KeratinoSens™ 77 63 73 188
h-CLAT 81 64 76 166
LuSens 76 67 73 77
(m)MUSST 73 74 73 150
n = number of substances analyzed.
Table 3
Cooper statistics for the single non-animal test methods and the ‘2 out of 3’ approach when compared to human and LLNA data (subset B).
Chemical set and reference data Subset B
Human dataa LLNA data
Cooper statistics Se [%] Sp [%] Acc [%] n Se [%] Sp [%] Acc [%] n
‘2 out of 3’ approach 90 90 90 101 81 83 82 103
DPRA 84 84 84 102 77 85 79 105
KeratinoSens™ 82 84 82 102 74 73 74 103
h-CLAT 89 64 82 98 86 68 81 101
LuSens 78 79 79 60 73 70 71 62
(m)MUSST 74 88 78 85 71 83 75 87
LLNA 91 64 82 111 – – – –
Se = sensitivity; Sp = speciﬁcity; Acc = accuracy; n = number of substances analyzed.
a a-Amyl cinnamic aldehyde, a-hexyl cinnamic aldehyde and 6-methyl coumarin could not ﬁnally be evaluated as human sensitizers or non-sensitizers and were thus
rated as ‘‘borderline’’.
Table 4
Substances with discordant test results among KeratinoSens™ and LuSens.
Name Cas # KeratinoSens™ LuSens
Final vs. LLNA vs. Human Final vs. LLNA Vs. Human
Farnesal 502-67-0 1 TP – 0 FN –
Ethylenediamine 107-15-3 1 TP TP 0 FN FN
Propyl gallate 121-79-9 1 TP TP 0 FN FN
Nickel chloride 7718-54-9 1 FP TP 0 TN FN
Methyl salicylate 119-36-8 0 TN TN 1 FP FP
Benzyl alcohol 100-51-6 0 TN FN 1 FP TP
Eugenol 97-53-0 0 FN FN 1 TP TP
a-Hexyl cinnamic aldehyde 101-86-0 Bord. – – 1 TP –
1, positive overall outcome; 0, negative overall outcome; bord., borderline outcome; TN/TP, true negative/positive; FN/FP, false negative/positive.
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approach instead of the KeratinoSens™, Cooper statistics estimated
an accuracy of 83% or 93%, when compared to LLNA or human data,
respectively.
Regarding the h-CLAT (Kao and Shiseido) and the (m)MUSST
(BASF and P&G), a common set of 105 substances was tested to
investigate dendritic cell activation. The same overall outcome
for 76 of 105 substances resulted in an interchangeability of 72%.
The 29 substances with discordant results can be found in Supple-
mentary Table (supporting information). The h-CLAT offered an
accuracy of 80% or 86% and the (m)MUSST an accuracy of 75% or
78%, when comparing the predictions to LLNA or human data,
respectively. The implementation of the h-CLAT into a ‘2 out of 3’
approach with DPRA and KeratinoSens™ data for the set of 105
substances resulted in an accuracy of 85% or 91%, when comparing
the predictions to LLNA or human data, respectively. If the
(m)MUSST was used for this approach instead of the h-CLAT, Coo-
per statistics estimated an accuracy of 81% or 90%, when compared
to LLNA or human data, respectively.3.4. Predictivities for groups of substances
3.4.1. Mechanistic domains by protein-binding mechanisms
Several means for grouping of substances into speciﬁc chemical
classes are possible, and the chosen approach may depend on the
speciﬁc purpose (Aptula et al., 2005). The molecular initiating
event (MIE) starting the skin sensitization process is the binding
of haptens to proteins. In order to analyze if the non-animal test
methods may detect classes of substances with different reaction
mechanisms with similar performances, nine different mechanistic
domains were deﬁned (Table 4). The probable protein-binding
mechanisms were assigned by the OECD QSAR Toolbox v3.2. Pro-
tein-binding mechanisms described in the scientiﬁc literature
were added to build a mechanistic chemistry framework for the
213 substances (Roberts and Aptula, 2014; Karlberg et al., 2013;
Aptula et al., 2009, 2007, 2005; Patlewicz et al., 2008; Roberts
et al., 2007a) (Supplementary Table). For 11 substances, two possi-
ble protein-binding mechanisms were proposed to be probable. For
example, maleic anhydride is supposed to react both as an acylat-
Table 5
Proposed mechanistic domains assigned by the OECD QSAR Toolbox, literature search and expert judgment as well as number and percentage of positive LLNA results within each
mechanistic domain.
Protein-binding mechanism n n of positives in LLNA
No protein-binding mechanisms assigned (no alert) 65 17 (26%)
Acylating agents (Ac) 21 19 (91%)
Michael acceptors (MA) 45 41 (91%)
Quinone precursors (QP) 22 19 (86%)
Schiff ‘base formers (SB) 30 25 (83%)
Substances reacting by nucleophilic substitutions of type 1 or 2 (SN1/2) 30 26 (87%)
Aromatics reacting by nucleophilic substitutions (SNAr) 6 6 (100%)
Substances reacting by a nucleophilic addition 1 1 (100%)
Metal ions forming coordination bonds 4 2 (50%)
Total (including two possible protein-binding mechanism for 11 substances) 224 –
n = number of substances analyzed.
Table 6
Total number of analyzed substances, number of TP, FN, TN, FP and accuracies for
each non-animal test method and the ‘2 out of 3’ approach for substances whose
molecular structures do not contain any obvious alerts for protein reactivity.
No reaction mechanism assigned
(n = 65)
Set A Subset B
LLNA data Human data LLNA data
DPRA n total 61 34 34
TP/FN 5/11 2/4 3/8
TN/FP 36/9 24/4 20/3
Accuracy [%] 67 76 68
KeratinoSens™ n total 55 33 33
TP/FN 5/9 3/3 2/8
TN/FP 31/10 24/3 19/4
Accuracy [%] 65 82 64
LuSens n total 30 25 25
TP/FN 1/5 2/1 1/4
TN/FP 17/7 18/4 15/5
Accuracy [%] 60 80 64
h-CLAT n total 48 29 29
TP/FN 10/4 3/3 6/3
TN/FP 22/12 14/9 14/6
Accuracy [%] 67 59 69
(m)MUSST n total 47 28 28
TP/FN 4/6 3/2 3/5
TN/FP 28/9 20/3 17/3
Accuracy [%] 68 82 71
‘2 out of 3’ approach n total 51 30 30
TP/FN 7/8 2/3 3/7
TN/FP 30/6 22/3 18/2
Accuracy [%] 73 80 70
n, number of substances analyzed; TN/TP, true negative/positive; FN/FP, false
negative/positive.
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was not possible to assess whether a chemical may react either in a
SN1 or SN2 reaction. Thus, both organic reaction types were placed
into one mechanistic domain. With exception of the one substance
reacting in a nucleophilic addition and the four metal containing
substances forming coordination bonds, all mechanistic domains
are described in more detail in the following sections.
3.4.1.1. No reaction mechanism assigned (no alert). This substance
group contains 65 substances whose molecular structures do not
contain any obvious alerts for protein reactivity. Many substances
in this group represent aliphatic alcohols, organic acids, nitriles,
amides, a,b-saturated esters or simple dialkylketones. Accuracies
for the non-animal tests calculated within this substance group
were compared to LLNA and human data. One aspect which should
be taken into account is that the predictivities are inﬂuenced by
the number and type of substances being assessed and data sets
may therefore vary in this study. DPRA data, which directly indi-
cate peptide reactivity, were available for 61 substances in this
group. The accuracy of the DPRA was 67% when compared to LLNA
data or 76% when compared to human data. Regarding keratino-
cyte activation, the KeratinoSens™ offered an accuracy of 65% or
82% and the LuSens an accuracy of 60% or 80%, when comparing
the predictions to LLNA or human data, respectively. Regarding
dendritic cell activation, the accuracy of the h-CLAT was 67% or
59% and that of the (m)MUSST was 68% or 82% when compared
to LLNA or human data, respectively. Using the ‘2 out of 3’
approach, 73% or 80% of the substances were correctly identiﬁed
in this domain when compared to LLNA or human data, respec-
tively. The number of tested substances and predictions is given
in Table 5.
3.4.1.2. Acylating agents (Ac). In an acylation, acyl moieties can be
transferred to the nucleophilic centers of proteins. This mechanis-
tic domain contains 21 acylating agents like esters of acidic alco-
hols (e.g. phenol esters) or carboxylic anhydrides. Accuracies for
the non-animal tests calculated for the substances within this
domain were compared to LLNA and human data. The accuracy
of the DPRA was 100% or 82% when compared to LLNA or human,
respectively. The ARE-based assays did not allow a reliable predic-
tion of the sensitization potential of substances in this domain. The
KeratinoSens™ offered an accuracy of 56% or 58% and the LuSens
an accuracy of 44% or 50%, when comparing the predictions to
LLNA or human data, respectively. Regarding dendritic cell activa-
tion test methods, Cooper statistics estimated an accuracy of 88%
or 83% for the h-CLAT and an accuracy of 69% or 56% for the
(m)MUSST, when compared to LLNA or human data, respectively.
Using the ‘2 out of 3’ approach, 88% or 83% of the substances were
correctly identiﬁed in this domain when compared to LLNA orhuman data, respectively. The number of substances, accuracies
and number of correct or incorrect predictions can be found in
Table 6.
3.4.1.3. Michael acceptors (MA). MAs contain a,b-unsaturated ester,
ketone or aldehyde functions. a,b-unsaturated alcohols can also
react as MAs after the alcohol group is oxidized to an aldehyde
(Karlberg et al., 2013). Due to their high probability to react as
MAs, quinone precursors could also be placed into this domain
(Aptula et al., 2009), but are handled as a separate substance
domain on account of their speciﬁc structural characteristics. This
mechanistic domain contains 45 Michael acceptors. Accuracies for
the non-animal tests calculated within this mechanistic domain
were compared to LLNA and human data. In this domain, the DPRA
provided an accuracy of 81% when compared to LLNA data or 86%
when compared to human data. The KeratinoSens™ offered an
accuracy of 85% or 100% and the LuSens an accuracy of 88% or
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respectively. Regarding dendritic cell activation, Cooper statistics
estimated an accuracy of 92% or 90% for the h-CLAT and an accu-
racy of 86% or 80% for the (m)MUSST, when compared to LLNA
or human data, respectively. Using the ‘2 out of 3’ approach, 88%
or 95% of the substances were correctly identiﬁed in this domain
when compared to LLNA or human data, respectively. The number
of substances, accuracies and number of correct or incorrect pre-
dictions can be found in Table 7.
3.4.1.4. Quinone precursors. This mechanistic domain contains di-
or poly-substituted aromatic compounds with alkoxy, hydroxyl
or amine residues. These compounds are pre- or pro-haptens and
thus require abiotic or metabolic oxidation to form quinones, qui-
none imines or quinone methides. These oxidation products are
most likely to react as Michael acceptors (free radical binding via
Wuerster-type radical may also be possible) (Aptula et al., 2009).
22 substances were identiﬁed as possible quinone precursors.
Accuracies for the non-animal test methods calculated within this
mechanistic domain were compared to LLNA and human data. In
this domain, the DPRA provided an accuracy of 71% when com-
pared to LLNA data or 91% when compared to human data. Regard-
ing keratinocyte activation, the KeratinoSens™ offered an accuracy
of 79% or 90% and the LuSens an accuracy of 71% or 71%, when
comparing the predictions to LLNA or human data, respectively.
However, only 7 substances (set A and B) in this domain have
LuSens data. Regarding dendritic cell activation, Cooper statistics
estimated an accuracy of 94% or 91% for the h-CLAT and an accu-
racy of 83% or 80% for the (m)MUSST, when compared to LLNA
or human data, respectively. Using the ‘2 out of 3’ approach, 83%
or 91% of the substances were correctly identiﬁed in this domain
when compared to LLNA or human data, respectively. The number
of substances, accuracies and number of correct or incorrect
predictions can be found in Table 8.Table 7
Total number of analyzed substances, number of TP, FN, TN, FP and accuracies for
each non-animal test method and the ‘2 out of 3’ approach for possible acylating
agents.
Acylating agents (n = 21) Set A Subset B
LLNA data Human data LLNA data
DPRA n total 19 11 11
TP/FN 17/0 9/1 10/0
TN/FP 2/0 0/1 1/0
Accuracy [%] 100 82 100
KeratinoSens™ n total 18 12 12
TP/FN 10/6 6/5 5/6
TN/FP 0/2 1/0 0/1
Accuracy [%] 56 58 42
LuSens n total 9 6 6
TP/FN 4/4 2/3 2/4
TN/FP 0/1 1/0 0/0
Accuracy [%] 44 50 33
h-CLAT n total 16 12 12
TP/FN 12/2 9/2 9/2
TN/FP 2/0 1/0 1/0
Accuracy [%] 88 83 83
(m)MUSST n total 16 9 9
TP/FN 9/5 5/4 5/3
TN/FP 2/0 0/0 1/0
Accuracy [%] 69 56 67
‘2 out of 3’ approach n total 16 12 12
TP/FN 12/2 9/2 9/2
TN/FP 2/0 1/0 1/0
Accuracy [%] 88 83 83
n, number of substances analyzed; TN/TP, true negative/positive; FN/FP, false
negative/positive.3.4.1.5. Schiff ‘base formers (SB). Aldehydes and activated ketones
predominantly react with hard nucleophiles to form imines (Schiff
‘bases). Pre/pro-SB formers like primary amines were also included
in this domain (Foussereau et al., 1983) as well as 1,3 dicarbonyl
compounds due to their tendency to enolize (Roberts et al.,
2007b). Aromatic aldehydes of the general formula ArCHO were
assigned to this domain, although a non-sensitizing effect of this
alert is discussed in the literature (Patlewicz et al., 2001). In total,
30 of the 213 substances were supposed to react as Schiff ‘base
formers. Regarding peptide reactivity, the DPRA provided an accu-
racy of 65% when compared to LLNA data or 77% when compared
to human data. The KeratinoSens™ offered an accuracy of 66% or
79% and the LuSens an accuracy of 75% or 86%, when comparing
the predictions to LLNA or human data, respectively. However,
only 8 (set A) or 7 substances (subset B) in this domain have
LuSens data. Regarding dendritic cell activation, Cooper statistics
estimated an accuracy of 75% or 93% for the h-CLAT and an accu-
racy of 64% or 75% for the (m)MUSST, when compared to LLNA
or human data, respectively. Using the ‘2 out of 3’ approach, 69%
or 92% of the substances were correctly identiﬁed in this domain
when compared to LLNA or human data, respectively. The number
of substances, accuracies and number of correct or incorrect pre-
dictions can be found in Table 9.
3.4.1.6. Nucleophilic substitutions (SN1/2). Nucleophilic substitu-
tions exchange a moiety of a molecule (leaving group) for an
attacking nucleophilic group. This can be a concerted reaction
(SN2) or stepwise with the intermediate formation of a carbocation
(SN1). Since a clear distinction of the reaction order is not always
possible and the reaction products are identical (except for stereo-
chemistry), both reaction types were placed into one mechanistic
domain. The accuracy of the DPRA was 73% when compared to
LLNA data or 100% when compared to human data. The Keratino-
Sens™ offered an accuracy of 88% or 83% and the LuSens an accu-Table 8
Total number of analyzed substances, number of TP, FN, TN, FP and accuracies for
each non-animal test method and the ‘2 out of 3’ approach for possible Michael
acceptors.
Michael acceptors (n = 45) Set A Subset B
LLNA data Human data LLNA data
DPRA n total 42 22 22
TP/FN 32/6 18/3 18/3
TN/FP 2/2 1/0 1/0
Accuracy [%] 81 86 86
KeratinoSens™ n total 41 21 21
TP/FN 35/2 20/0 19/1
TN/FP 0/4 1/0 0/1
Accuracy [%] 85 100 90
LuSens n total 17 10 10
TP/FN 15/1 10/0 10/0
TN/FP 0/1 0/0 0/0
Accuracy [%] 88 100 100
h-CLAT n total 37 20 20
TP/FN 30/3 18/1 19/0
TN/FP 4/0 0/1 1/0
Accuracy [%] 92 90 100
(m)MUSST n total 29 15 15
TP/FN 22/3 12/3 12/2
TN/FP 2/1 0/0 1/0
Accuracy [%] 83 80 87
‘2 out of 3’ approach n total 43 22 22
TP/FN 36/3 20/1 20/1
TN/FP 2/2 1/0 1/0
Accuracy [%] 88 95 95
n, number of substances analyzed; TN/TP, true negative/positive; FN/FP, false
negative/positive.
Table 9
Total number of analyzed substances, number of TP, FN, TN, FP and accuracies for
each non-animal test method and the ‘2 out of 3’ approach for possible quinone
precursors.
Quinone precursors (n = 22) Set A Subset B
LLNA data Human data LLNA data
DPRA n total 21 11 11
TP/FN 14/5 10/1 10/1
TN/FP 1/1 0/0 0/0
Accuracy [%] 71 91 91
KeratinoSens™ n total 19 10 10
TP/FN 14/3 9/1 9/1
TN/FP 1/1 0/0 0/0
Accuracy [%] 79 90 90
LuSens n total 7 7 7
TP/FN 4/2 4/2 4/2
TN/FP 1/0 1/0 1/0
Accuracy [%] 71 71 71
h-CLAT n total 16 11 11
TP/FN 13/1 9/1 9/1
TN/FP 2/0 1/0 1/0
Accuracy [%] 94 91 91
(m)MUSST n total 18 10 10
TP/FN 14/2 8/2 8/2
TN/FP 1/1 0/0 0/0
Accuracy [%] 83 80 80
‘2 out of 3’ approach n total 18 11 11
TP/FN 14/3 10/1 10/1
TN/FP 1/0 0/0 0/0
Accuracy [%] 83 91 91
n, number of substances analyzed; TN/TP, true negative/positive; FN/FP, false
negative/positive.
Table 10
Total number of analyzed substances, number of TP, FN, TN, FP and accuracies for
each non-animal test method and the ‘2 out of 3’ approach for Schiff ‘base formers.
Schiff ‘base formers (n = 30) Set A Subset B
LLNA data Human data LLNA data
DPRA n total 26 13 13
TP/FN 15/7 12/1 11/1
TN/FP 2/2 0/0 0/0
Accuracy [%] 65 77 85
KeratinoSens™ n total 29 14 14
TP/FN 18/7 11/3 10/3
TN/FP 1/3 0/0 0/1
Accuracy [%] 66 79 71
LuSens n total 8 7 7
TP/FN 6/1 5/1 5/1
TN/FP 0/1 1/0 1/0
Accuracy [%] 75 86 86
h-CLAT n total 24 14 14
TP/FN 15/5 12/1 11/1
TN/FP 3/1 1/0 1/1
Accuracy [%] 75 93 86
(m)MUSST n total 22 12 12
TP/FN 13/6 9/3 8/3
TN/FP 1/2 0/0 0/1
Accuracy [%] 64 75 67
‘2 out of 3’ approach n total 26 13 13
TP/FN 17/6 12/1 11/1
TN/FP 1/2 0/0 0/1
Accuracy [%] 69 92 85
n, number of substances analyzed; TN/TP, true negative/positive; FN/FP, false
negative/positive.
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human data, respectively. However, only 6 (set A) or 5 substances
(subset B) in this domain have LuSens data. Regarding dendritic
cell activation, Cooper statistics estimated an accuracy of 59% or
92% for the h-CLAT and an accuracy of 64% or 75% for the
(m)MUSST, when compared to LLNA or human data, respectively.
Using the ‘2 out of 3’ approach, 76% or 100% of the substances were
correctly identiﬁed in this domain when compared to LLNA or
human data, respectively. The number of substances, accuracies
and number of correct or incorrect predictions can be found in
Table 10.
3.4.1.7. Nucleophilic substitutions in aromatic compounds (SNAr). A
speciﬁc case of nucleophilic substitution takes place in aromatic
compounds with electron-withdrawing groups. Within this study,
only six substances were assigned to this domain whereby only
two had human data. Therefore, Cooper statistics were only calcu-
lated against LLNA data (set A). The accuracies of the single assays
ranged from 75% to 100% (DPRA: 100%, KeratinoSens™: 83%,
LuSens: 100%, h-CLAT: 100%, (m)MUSST: 75%) and the accuracy
of the ‘2 out of 3’ approach achieved 100% within this mechanistic
domain.
3.4.1.8. Pre- and pro-haptens. The class of pre- and pro-haptens rep-
resents substances which require abiotic (e.g. via autoxidation) or
biotic (e.g. via metabolic pathways) activation, respectively, in
order to become electrophilic. Opposite to pro-haptens, the activa-
tion of pre-haptens could be prevented by precautionary measures
in the handling and storage of the substances (Gerberick et al.,
2008). Nevertheless, pre- and pro-haptens are not always distinct
since autoxidation and metabolic oxidation can result in the same
product, although the underlying mechanisms may differ (Karlberg
et al., 2013). Since pre-haptens may also be pro-haptens and vice
versa no distinction between substances requiring biotic andabiotic activation was made. The data set contains at least 30
pre/pro-haptens (compare Supplementary Table). The ‘2 out of 3’
approach could be performed for 25 substances within this domain
and resulted in 21 correct predictions, when compared to LLNA
data (accuracy = 84%).
4. Discussion
With the compilation of currently available non-animal test
method results for the distinction of skin sensitizers and non-sen-
sitizers the database could be enlarged to a set of 213 substances.
Included in the present dataset are 54 and 145 substances pub-
lished previously by Bauch et al. (2012) and Natsch et al. (2013),
respectively, whereby 41 substances were reported in both studies.
4.1. Predictivities
Compared to the predictivity described by Bauch et al. (2012)
and Natsch et al. (2013), the performance of the investigated
non-animal test methods is generally slightly lower when analyz-
ing the data set of 213 substances (Table 12). For example, the
DPRA provided an accuracy of 79% for 52 substances in Bauch
et al. (2012) and 75% for 194 substances in the current study (both
compared to LLNA data). This difference may simply reﬂect the
variations occurring with various datasets on the one hand, but
on the other hand newly developed methods are often ﬁrst com-
pared against ‘gold-standard’ lists of chemicals with the most con-
sistent in vivo evidence from multiple tests and test methods,
while upon expansion of the database chemicals are included for
which, e.g. only a single LLNA study is available. In this regard,
the degree of variability of the in vivo method needs to be kept
in mind. In the light of hazard prediction 15.7% of the investigated
non-sensitizers were falsely predicted as sensitizers in repeated
experiments and 3.1% of sensitizers were falsely predicted as
Table 11
Total number of analyzed substances, number of TP, FN, TN, FP and accuracies for
each non-animal test method and the ‘2 out of 3’ approach for substance reacting in
nucleophilic substitutions of type 1 or 2.
Nucleophilic substitutions (SN1/2)
(n = 30)
Set A Subset B
LLNA data Human data LLNA data
DPRA n total 26 11 11
TP/FN 18/4 9/0 9/0
TN/FP 1/3 2/0 0/2
Accuracy [%] 73 100 82
KeratinoSens™ n total 26 12 12
TP/FN 22/0 10/0 10/0
TN/FP 1/3 0/2 2/0
Accuracy [%] 88 83 100
LuSens n total 6 5 5
TP/FN 6/0 5/0 5/0
TN/FP 0/0 0/0 0/0
Accuracy [%] 100 100 100
h-CLAT n total 27 12 12
TP/FN 14/9 9/1 9/2
TN/FP 2/2 2/0 0/1
Accuracy [%] 59 92 75
(m)MUSST n total 17 9 9
TP/FN 10/5 7/1 7/1
TN/FP 2/0 1/0 0/1
Accuracy [%] 64 75 78
‘2 out of 3’ approach n total 25 12 12
TP/FN 18/3 10/0 10/0
TN/FP 1/3 2/0 0/2
Accuracy [%] 76 100 83
n, number of substances analyzed; TN/TP, true negative/positive; FN/FP, false
negative/positive.
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performance standards in the standard LLNA protocol, a reproduc-
ibility of only 77% was found for the investigated substances (Kolle
et al., 2013).
In addition to evaluating the results of the single test methods,
the overall yes/no-ratings of the ‘2 out of 3’ prediction models from
the previously published studies and the current study was com-
pared (Table 12). The ‘2 out of 3’ prediction model in Bauch et al.
(2012) consisted of the DPRA, LuSens and mMUSST. An overall
accuracy of 83% and 94% compared to LLNA or human data, respec-
tively, was achieved. Natsch et al. (2013) used the DPRA, Keratino-
Sens™ and MUSST in their ‘2 out of 3’ prediction model andTable 12
Performances of the investigated non-animal test methods and the ‘2 out of 3’ approach i
Bauch et al.
Acc [%]
Compared to LLNA data
Peptide reactivity DPRA 79
KC activation KeratinoSens™ 81
LuSens 77
DC activation (m)MUSST 74
h-CLAT –
Compared to human data
Peptide reactivity DPRA 86
KC activation KeratinoSens™ 80
LuSens 84
DC activation (m)MUSST 86
h-CLAT –
Prediction model
’2 out of 3’ approacha (vs. LLNA data) 83
’2 out of 3’ approacha (vs. human data) 94
Acc, accuracy; n, number of analyzed substances; KC, keratinocyte; DC, dendritic cell; ‘‘
a 2 out of 3’ prediction model in Bauch et al. (2012) (DPRA, LuSens, mMUSST) and Nats
the prediction model underlying this paper (DPRA, KeratinoSens™, h-CLAT).reported a similar accuracy for 145 substances (81% compared to
LLNA). In the current study, the results of the DPRA, KeratinoSens™
and h-CLAT were used for applying this prediction model. Table 12
illustrates, that all three ‘2 out of 3’ prediction models provide very
similar and high overall accuracies. Even though the dataset was
expanded from 54 to 180 substances the accuracy is still similar
when compared to the LLNA; 79% compared to 83% in the Bauch
et al. study and 81% in the Natsch et al. study. Compared to human
data, the accuracies reported in Bauch et al. (2012) and in the cur-
rent study are very similar (94% and 90%, respectively), although
the current analysis is based on an almost twofold larger dataset.
The higher accuracy when comparing to human instead of LLNA
data indicates that the investigated non-animal test methods pre-
dict human data more accurately than LLNA data.
In addition, the direct comparison of LLNA data to human data
revealed an overall accuracy of 82% of the LLNA. The ‘2 out of 3’
prediction model however revealed an accuracy of 90% when com-
pared to human data for the same set of substances. This indicates
that the ‘2 out of 3’ predictions might be more relevant for humans
than the LLNA predictions. However, some of the substances with
different in vivo outcomes are pre-haptens (e.g. limonene, citronel-
lol or linalool). This could be one reason for discordant LLNA and
human results, since pre-hapten activation could be prevented by
precautionary measures in handling or storage (Gerberick et al.,
2008). But this does not imply that pre-haptens are not possibly
a risk for humans. Substances leading to different predictions in
the LLNA, human tests and the ‘2 out of 3’ are discussed in more
detail in the following part.
4.2. False negative and false positives
The discussion of false predictions provided by the single non-
animal test methods would be beyond the scope of this study.
Hence, the analysis was restricted to the detailed investigation of
false positive and false negative predictions by the ‘2 out of 3’
approach, when compared to LLNA and human data. The 28 sub-
stances leading to false negative results are divided into 4 groups
and possible explanations for the discrepancy are discussed indi-
vidually (Table 13). In brief, in group FN-1 negative human data
conﬁrm the negative overall results of the non-animal test meth-
ods for 11 substances (the LLNA is over-predictive for this set of
substances). For the three substances in group FN-2 (diethylenetri-
amine, resorcinol and benzoyl peroxide) concordant human andn different datasets.
(2012) Natsch et al. (2013) This paper
n Acc [%] n Acc [%] n
54 80 145 75 194
54 77 145 73 188
54 – – 73 77
54 71 141 73 149
– – – 76 166
51 – – 84 102
51 – – 82 102
51 – – 79 61
51 – – 78 85
– – – 82 98
54 81 145 79 180
51 – – 90 101
–’’, no data available or data not considered in this study.
ch et al. (2013) (DPRA, KeratinoSens™, MUSST) were slightly different compared to
Table 13
False negative predictions within the ‘2 out of 3’ approach.
Chemical name CAS # LLNA EC3 Discussion
Group FN-1 ‘2 out of 3’ approach (), LLNA (+), human ()
Phthalic anhydride 85-44-9 0.16 Respiratory sensitizer, but no skin sensitizer (Dearman et al., 2013); LLNA
probably FP
a-iso-Methylionone 127-51-5 21.8 In HRIPTa no induction at 70,866 lg/cm2; LLNA probably FP
Xylene 1330-20-7 95.8 No evidence for skin sensitization in humans (Basketter et al., 2014); LLNA
probably FP
Pyridine 110-86-1 71.2 No evidence for skin sensitization in humans (Schneider and Akkan, 2004); LLNA
probably FP
Isopropyl myristate 110-27-0 44 No evidence for skin sensitization in humans (Basketter et al., 2014); LLNA
probably FP
Linalool 78-70-6 30 No or weak evidence in humans with no induction in HRIPTa at 15,000 lg/cm2;
LLNA possibly FP
Sodium dodecyl sulfate (SDS) 151-21-3 14 Well characterized false positive response in LLNA, no evidence for skin
sensitization in humans (Basketter et al., 2014); LLNA probably FP
Hexyl salicylate 6259-76-3 0.18 In HRIPTa no induction at 35,433 lg/cm2 and in HMTa no induction at 20,654 lg/
cm2; LLNA probably FP
DL-a-Tocopherol 10191-41-0 7.4 No evidence for skin sensitization in humans (Basketter et al., 2014); LLNA
probably FP
Benzyl benzoate 120-51-4 17 No or only weak evidence in humans (Basketter et al., 2014) with no induction
in HRIPTa at 59000 lg/cm2; LLNA probably FP
Benzyl salicylate 118-58-1 2.9 No or only weak evidence in humans (Basketter et al., 2014); in HRIPTa no
induction at 17,717 lg/cm2 and in HMTa no induction at 20,690 lg/cm2; LLNA
probably FP
Group FN-2 ‘2 out of 3’ approach (), LLNA (+), human (+)
Benzoyl peroxide 94-36-0 0.004 Well-known contact allergen in humans (Basketter et al., 2014), clearly positive
in DPRA
Resorcinol 108-46-3 5.5 Known contact allergen in humans after considerable exposure (Basketter et al.,
2014); positive in h-CLAT and MUSSTb
Diethylenetriamine 111-40-0 5.8 Positive in HMT (Kligman, 1966b), all non-animal tests negative, putative pro-
hapten
Group FN-3 ‘2 out of 3’ approach (), LLNA (+), human (no or conﬂicting data)
a-Hexyl cinnamic aldehyde 101-86-0 11.97 Inconclusive human data; borderline in KeratinoSens™, positive in LuSens2 and
MUSSTb
N,N-Dibutylaniline 613-29-6 19.6 Putative pro-hapten, all non-animal tests negative
2-Methoxy-4-methylphenol 93-51-6 5.8 Putative pro-hapten, positive in h-CLAT and MUSSTb
3-Aminophenol 591-27-5 3.2 Putative pro-hapten, positive in h-CLAT and MUSST
2,2,6,6-Tetramethyl-3,5-heptanedione 1118-71-4 27 All non-animal tests negative
3-Methyl-1-phenylpyrazolone 89-25-8 8.5 All non-animal tests negative
Undec-10-enal 112-45-8 6.8 Positive in KeratinoSens™
Squaric acid diethyl ester 5231-87-8 0.9 All non-animal tests negative
Methyl pyruvate 600-22-6 2.4 All non-animal tests negative
Benzyl cinnamate 103-41-3 18.4 Positive in KeratinoSens™
Group FN-4 ‘2 out of 3’ approach (), LLNA (), human (+)
Coumarin 91-64-5 NC Well-known contact allergen in humans (Basketter 2014-62), positive in
KeratinoSens™
Streptomycin sulfate 3810-74-0 NC Positive in HMT (Kligman, 1966a)
Kanamycin 8063-07-8 NC Known contact allergen in humans after considerable exposure (Schneider and
Akkan, 2004)
Benzyl alcohol 100-51-6 NC Positive in HMTa at 8858 lg/cm2
a HRIPT and HMT data were found in the data base of the Research Institute for Fragrance Materials (RIFM).
b DPRA, KeratinoSens™ and h-CLAT results were considered for ‘2-out-of-3’ approach.
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hint that the negative outcome in the ‘2 out of 3’ approach is false.
Diethylenetriamine and resorcinol are putative pro-haptens. They
are not detectable in the cell-free DPRA and may not be activated
in the cellular assays due to a limited metabolic capacity (Fabian
et al., 2013; Oesch et al., 2014). Benzoyl peroxide was strongly
positive in the DPRA but negative in the KeratinoSens™ and h-
CLAT. The ten substances in group FN-3 were tested positively by
LLNA, but no human data are available. Group FN-4 contains four
substances which are true negatives when compared to LLNA data
but false negatives, when compared to human data. Among these
are the two water soluble antibiotics streptomycin and kanamycin.
Both are negative in all investigated non-animal tests and also in
the LLNA, but decades of human use indicate an incidence for an
ACD after considerable exposure (Kligman, 1966b; Schneider and
Akkan, 2004). These oligoaminoglucosides are structurallysigniﬁcantly different from all other known haptens and pre-/
pro-haptens and it is still not clear whether they sensitize by the
classical hapten-based mechanism.
Similar to the discussion of the false negative results, also the
overall 15 false positive substances could be divided into 4 groups
(Table 14). In group FP-1 positive human data conﬁrm the positive
overall results of the non-animal test methods and identify the
LLNA to be under-predictive for the three substances benzocaine,
benzaldehyde and nickel chloride in this group. Benzocaine and
benzaldehyde are known contact allergens in humans but only
after considerable exposure (Griem et al., 2003) (RIFM database).
Hence, the possibility of a false negative response in the LLNA
has to be considered. Nickel chloride directly activates the human
Toll-like receptor 4 (TLR4). As the mouse cannot mount this TLR4
based response (Schmidt et al., 2010), this indicates a true and well
recognized false negative LLNA result. Group FP-2 with concordant
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ben, which was tested positively in the KeratinoSens™ and h-CLAT.
Although some positive human patch test results are described in
the literature, the frequent use of parabens in general corroborates
this class to be non-sensitizers from a regulatory point of view
(Schnuch et al., 2011; Basketter et al., 2006). Group FP-3 contains
nine substances which were predicted to be sensitizers within
the ‘2 out of 3’ approach but are non-sensitizers according to LLNA
data. For these substances no human data were found in the liter-
ature. Peptide adduct formation was detected in a modiﬁed pep-
tide reactivity test using LC–MS detection (Natsch et al.,
submitted for publication) for six substances within this group
(i.e. 2-hydroxypropyl methacrylate, 2-acetyl-cyclohexanone, furil,
1-bromobutane, 1-iodohexane and methyl-3-bromopropionate)
which indicates that the positive outcome of the ‘2 out of 3’ predic-
tion model might possibly be correct as these are clearly protein-
modifying haptens. Group FP-4 contains R(+)-limonene and D,L-cit-
ronellol. For both, negative human data are described in the liter-
ature (Basketter et al., 2014). Thus, human data are supposed to
overrule the positive overall outcome of the non-animal test meth-
ods as well as the positive LLNA results. For citronellol, also a
recent LLNA on highly pure material was negative (Rudback
et al., 2014). However, under the EU Cosmetics Regulation both
limonene and citronellol are considered to be allergens although
only oxidative metabolites may be reactive suggesting probable
pre-/pro-haptens.
4.3. Integrated and sequential testing strategies
From the 144 chemicals with clear-cut results in all three tests
(DPRA, KeratinoSens™ and h-CLAT), a congruent result in all three
tests was obtained in 76 cases (‘3 out of 3’), while for 68 cases a ‘2
out of 3’ assessment was made. For an additional set of 36 chemi-
cals the prediction model is based on a ‘2 out of 2’ assessment from
either the combination of DPRA and KeratinoSens™ (n = 24), Kera-
tinoSens™ and h-CLAT (n = 11) or DPRA and h-CLAT (n = 1).
The high overall accuracy of the ‘2 out of 3’ approach indicates
that in many cases positives or negatives in single assays are actu-
ally FP or FN, respectively, what underlines the importance of mak-
ing an majority voting. False-positives in the different assays might
be due to different mechanisms; thus in KeratinoSens™ unspeciﬁc
activation of the antioxidant response due to other mechanisms
than covalent modiﬁcation of Keap1 is possible, while false-posi-
tives in DPRA may be generated by unspeciﬁc peptide oxidation.
In the h-CLAT, non-sensitizing irritants such as octanoic acid may
also lead to surface marker expression. False negatives results
might occur due to solubility issue or limited metabolic or oxida-
tive activation. Among the 68 substances relying on two concor-
dant of three results (‘2 out of 3’), the DPRA and KeratinoSens™
rule the ‘2 out of 3’ overall prediction in 24 cases, the DPRA and
h-CLAT in 29 cases and the KeratinoSens™ and h-CLAT in 15 cases.
At the same time this analysis indicates that to arrive at the
ﬁnal conclusions often not all three tests are needed, as with two
congruent tests the third assay can be waived as it would not
change the assessment. This was actually applied in 36 cases with
a congruent result in 2 out of 2 tests.
4.4. Interchangeabilities
Within the current dataset both the KeratinoSens™ and the
LuSens assay cover the AOP key event ‘activation of keratinocytes’.
For a common subset of 69 substances an interchangeability of 88%
could be calculated. Only 8 test substances did not provide concor-
dant data among both assays (Table 11). Reasons for the different
results might be due to differences in the test procedures (e.g. cyto-
toxicity range ﬁnders), the nature of the used ARE sequence in thekeratinocyte cell line (e.g. in KeratinoSens™ and LuSens derived
from human or rat, respectively), putative differential metabolic
capacities of the cell lines (four substances were pro-haptens) or
incidental (borderline read-out in one case). In addition, some of
these differences could be also related to the different prediction
models used, for instance, the KeratinoSens™ only requires one
single concentration of the test substance yielding an induction
higher than 1.5-fold whereas the LuSens requires at least two con-
secutive concentrations. A detailed discussion of the similarity of
both assays can be found in Ramirez et al. (2014). Compared to
human and LLNA data, both assays provide comparable Cooper sta-
tistics. And also the use of the LuSens assay instead of the Kerati-
noSens™ within a ‘2 out of 3’ approach leads to similar
accuracies, although the available dataset of the LuSens is smaller
compared to the KeratinoSens™.
An interchangeability of only 72% was calculated for the h-CLAT
and the (m)MUSST that both cover the AOP key event ‘activation of
dendritic cells’. The MUSST and the mMUSST use slightly different
protocols, prediction models and cell lines. For the analyses within
this study, the results from the MUSST and mMUSST were taken
together and discordant results were excluded. When comparing
the results of a common subset to in vivo data, the (m)MUSST pro-
vides a slightly increased speciﬁcity whereas the h-CLAT provides
an increased sensitivity and overall accuracy. Reasons for the
higher sensitivity of the h-CLAT might be the additional marker
CD54 and the suitability for this speciﬁc common subset of sub-
stances. A detailed analysis of the CD54 and CD86 induction might
provide further valuable information.
4.5. Mechanistic domains
In order to analyze if the non-animal test methods may detect
classes of substances with different reaction mechanisms with
similar performances, nine different mechanistic domains were
deﬁned by probable protein-binding mechanisms of the 213 sub-
stances underlying this study (Table 4). One aspect which should
be taken into account is that the predictivities are inﬂuenced by
the number and type of substances being assessed and data sets
may therefore vary in this study. No reaction mechanism was
assigned for a group of substances (n = 65) with a lack of obvious
structural characteristics associated with skin sensitization. How-
ever, some of the substances in this group are sensitizing in the
LLNA or in humans (e.g. hexyl salicylate). In vivo evidence for hexyl
salicylate resulting from a single LLNA test provides the lowest EC3
value within this substance group (EC3 = 0.18, compare RIFM data
base). Like the structurally similar methyl salicylate, which was
tested negatively in the LLNA, the chemical structure of hexyl salic-
ylate reveals no obvious alert for peptide reactivity. Irritation is a
confounding factor in the LLNA since it leads to overestimations
of sensitization potentials (Ball et al., 2011). In addition, hexyl
salicylate was negative even at high concentrations in HRIPT
(NOEL  35,400 lg/cm2) and HMT (NOEL  20,600 lg/cm2) (com-
pare RIFM database). Therefore, the very low EC3 may well be
due to its irritating properties or possibly also due to sensitizing
impuities. Another substance which was sensitizing in both human
clinical trials and in the murine LLNA is abietic acid. Nevertheless,
abietic acid itself is considered to be a non-sensitizer, but depend-
ing on storage, sensitization via hydro peroxides derived from
autoxidation is probable (Roberts et al., 2007a). A further chemical
with a positive LLNA outcome in this group is the well-character-
ized irritant SDS (EC3 = 14%) (Gerberick et al., 2005; Ball et al.,
2011). SDS is considered to be the classic example of a substance
yielding a false positive response in the LLNA, what is also con-
ﬁrmed by negative human patch tests (Basketter et al., 2014). Like-
wise, anhydrous oxalic acid was tested positively in the LLNA
(EC3 = 15). This substance was further analyzed for its capacity to
Table 14
False positive predictions within the ‘2 out of 3’ approach.
Chemical name CAS # LLNA EC3 Discussion
Group FP-1 ‘2 out of 3’ approach (+), LLNA (), human (+)
Nickel chloride 7718-54-9 NC Well characterized false negative response in murine LLNA, most common contact
allergen in humans (Griem et al., 2003); LLNA probably FN
Benzocaine 94-09-7 NC Known contact allergen in humans after considerable exposure (Griem et al., 2003),
all non-animal tests positive; LLNA probably FN
Benzaldehyde 100-52-7 NC Positive HRIPT1a at 2760 lg/cm2, positive in KeratinoSens™, h-CLAT and MUSST;
LLNA probably FN
Group FP-2 ‘2 out of 3’ approach (+), LLNA (), human ()
Propyl paraben 94-13-3 NC No or only weak evidence in humans (Basketter et al., 2014)
Group FP-3 ‘2 out of 3’ approach (+), LLNA (), human (no or conﬂicting data)
2-Hydroxypropyl methacrylate 923-26-2 NC Only h-CLAT negative; peptide adduct formation in LC–MS test (Natsch et al.,
submitted for publication)
3-Phenoxypropiononitrile 3055-86-5 NC Only KeratinoSens™ negative
2-Acetyl-cyclohexanone 874-23-7 NC All non-animal tests positive; peptide adduct formation in LC–MS test (Natsch et al.,
submitted for publication)
4-Methyl-2-nitroanisole 119-10-8 NC Only DPRA negative
2-Fluoro-5-nitroaniline 369-36-8 NC Only h-CLAT negative
Furil 492-94-4 NC Only h-CLAT negative; peptide adduct formation in LC–MS test (Natsch et al.,
submitted for publication)
1-Bromobutane 109-65-9 NC Only KeratinoSens™ and MUSSTb negative; highly volatile; peptide adduct formation
in LC–MS test (Natsch et al., submitted for publication)
1-Iodohexane 638-45-9 NC Only MUSST negative; peptide adduct formation in LC–MS test (Natsch et al.,
submitted for publication)
Methyl-3-bromopropionate 3395-91-3 NC Only h-CLAT negative; peptide adduct formation in LC–MS test (Natsch et al.,
submitted for publication)
Group FP-4 ‘2 out of 3’ approach (+), LLNA (+), human ()
R(+)-Limonene 5989-27-5 69 No or only weak evidence in humans (Basketter et al., 2014); putative pro-hapten
D,L-Citronellol 106-22-9 43.5 No or only weak evidence in humans (Basketter et al., 2014); putative pro-hapten,
recent negative LLNA (Rudback et al., 2014)
a HRIPT and HMT data were found in the data base of the Research Institute for Fragrance Materials (RIFM).
b DPRA, KeratinoSens™ and h-CLAT results were considered for ‘2-out-of-3’ approach.
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not form any adducts in an LC–MS test (Natsch et al., submitted
for publication) and also provided negative results in the DPRA.
For this mechanistic group, accuracies of the single non-animal
test methods are in a range of 65–68% when compared to LLNA
data and 56–84% when compared to human data. The accuracies
provided by the ‘2 out of 3’ approach are 73% and 80% when com-
pared to LLNA or human data, respectively. If such substances as
exempliﬁed above with known in vivo sensitization potential and
a theoretical non-binding capacity were excluded from this group,
cooper statistics would have been higher. However, these data can-
not be disregarded. Thus, the aim should be extension of the
parameters used for assessment of the binding capacities and
include factors such as abiotic or enzymatic activation processes.
In contrast to the above discussed group of substances with a
lack of obvious structural characteristics being associated with
peptide reactivity, the following mechanistic domains containing
Michael acceptors, acylating agents, Schiff ‘base formers, quinone
precursors and substances reacting in nucleophilic substitutions
are discussed. The substances within the domain of Michael accep-
tors were predicted with a generally high accuracy of at least 80%
by all of the non-animal test methods. In this domain, human and
LLNA data are also concordant for most of the substances.
Somewhat lower accuracies were calculated for acylating
agents. The low accuracies of the KeratinoSens™ (56%, compared
to LLNA data) and LuSens (44%, compared to LLNA data) are related
to a lack of activation of the Keap1/Nrf-2 pathway. Molecular path-
way activation triggered in KeratinoSens™ and LuSens is linked to
cysteine reactivity with the Keap 1 sensor protein. However, acyl-
ating agents like anhydrides transfer their acyl moiety predomi-
nantly to lysine residues (Emter et al., 2013; Aptula et al., 2005).
Seven substances of the false negatives in the keratinocyte-based
assays show considerably increased lysine reactivity in the DPRA.In this mechanistic domain more weight should be given to DPRA
results, since the accuracy in this domain was 100% or 82%, when
compared to LLNA or human data, respectively. Similar to acylating
agents, short chain aldehydes and longer chain saturated alkanals
in the domain of Schiff ‘base formers represent hard electrophiles
preferring to react with hard nucleophiles like lysine residues
instead of cysteine residues (LoPachin and Gavin, 2014). In general,
the battery of non-animal test methods appears to be more sensi-
tive to cysteine-reactive substances, as the DPRA has a readout
depending on cysteine reactivity, the KeratinoSens™ and LuSens
are also dependent on cysteine binding to a signiﬁcant degree,
but also the CD86 expression may be associated with cysteine
reactivity (Natsch et al., 2013). This might explain the slightly
lower accuracies of most of the non-animal test methods within
the domain of Schiff ‘base formers. Quinone precursors act as
pro-Michael acceptors and must ﬁrst be activated in order to
become electrophilic, but other protein-binding mechanisms can-
not be ruled out for some of the substances (Roberts et al.,
2007a). Compared to the other non-animal test methods in this
substance domain, the DPRA provided the lowest accuracy of
71%, when compared to LLNA data. This can be explained by the
fact, that some members of this group might require enzymatic
activation, which is absent in the in chemico assay. The cell-based
test methods also have only limited metabolic capacities (Oesch
et al., 2014; Fabian et al., 2013) and thus have limitations in detect-
ing putative pro-haptens.
Regarding the domain of nucleophilic substitutions (SN1 and 2),
the DPRA yields false negative results for one pro-hapten (i.e. dim-
ethylbenz[a]anthracene) and four benzylic esters with common
structural alerts (i.e. benzyl benzoate, benzyl salicylate, butylbenzyl
phthalate and benzyl cinnamate). Concerning the latter, the ben-
zylic sp3 carbon atom is supposed to react as electrophile. The
resulting benzylic cation is resonance stabilized what indicates a
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trophiles might spontaneously react with water or other rival
nucleophilic reaction partners of themodel peptides such as hydro-
xyl ions or solvents what would explain the negative outcome and
the slightly decreased accuracy of the DPRA in this domain. This
would also be an explanation for the slightly decreased accuracies
found in the dendritic cell-based assays when compared to LLNA
data, although DC activation is not necessarily be associated with
protein binding potential of a compound. The domain of aromatics
that react by nucleophilic substitutions (SNAr, n = 6) is quite small
in this data set, although further data are described in the literature
(Roberts and Aptula, 2014). Also the number of metal ions forming
coordination bonds is small (n = 4). In contrast to the DC and KC
based assays, the applicability domain of DPRA is not deﬁned for
compounds containing metal ions.5. Conclusions
The compilation of non-animal test results provides a compre-
hensive reference dataset with additional information such as
physicochemical properties, types of use, proposed organic reac-
tion mechanisms as well as related in vivo reference data for 213
substances.
This study conﬁrms the utility of the ﬁve investigated non-ani-
mal test methods, i.e. DPRA, KeratinoSens™, LuSens, h-CLAT and
(m)MUSST, to predict the respectiveAOPkey eventwith ahigh accu-
racy. When implemented into a ‘2 out of 3’ test strategy, skin sensi-
tizers can be discriminated from non-sensitizers with a high
reliability be the use of these alternative methods. For several sub-
stances the ‘2 out of 3’ approach does not predict the outcome of
the LLNA. For those, human and LLNA data only show a limited con-
cordance. The direct comparison of both in vivo references demon-
strates that the non-animal test methods predict human data
more accurately (Accuracy = 90%) than LLNA data (Accuracy = 82%).
The expanded dataset was further used to deﬁne different
mechanistic domains by probable protein-binding mechanisms.
This approach shows that Michael acceptors, substances reacting
in nucleophilic substitutions and quinone precursors were pre-
dicted with the highest accuracies. In the domain of Schiff ‘base
formers as well as in the group of substances with a lack of obvious
alerts for peptide reactivity, accuracies were slightly decreased. In
the domain of acylating agents, the keratinocyte based assays show
mechanistically justiﬁable decreased predictivities. If a chemical is
supposed to react by acylation, more weight should be given to the
DC-based assays and especially the Lys reactivity in the DPRA. The
number of substances tested in some speciﬁc groups is still low
(only six aromatics reacting by nucleophilic substitutions (SNAr)
and four metal-containing complexes within this dataset). Overall,
assigning a test substance to a domain according to its protein
binding mechanisms offers a way to obtain a more accurate esti-
mate of the predictive performance of the individual non-animal
test methods as well as the overall ‘2 out of 3’ prediction.6. Outlook
In consideration of the obtained data, the presented strategy
can be integrated in the regulatory assessment of the skin sensiti-
zation hazard potential. For this purpose the ‘‘2 out of 3’’ results
should be interpreted under the consideration of the impact the
mechanistic domain of the pertinent compound has on the out-
come of the individual test method. Thus, the obtained experimen-
tal results of the non-animal test methods together with the
reliability of the data based on the mechanistic domain provide a
weight of evidence for predicting the hazard potential for the
induction of skin sensitization.Beside information for hazard assessment the reference stan-
dard dataset also contains concentration–response data on the
non-animal test methods and potency information based on LLNA
and in part on human data. Therefore, this reference database may
further be used to develop prediction models for skin sensitization
potential and in particular it may be used to analyze how to arrive
at skin sensitization potency predictions based on current data.
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